2
Views
0
CrossRef citations to date
0
Altmetric
Correspondence

C-kit positive amelanotic melanoma of the oesophagus: a potential diagnostic pitfall

, , , , &
Pages 527-530 | Published online: 06 Jul 2009

  • Sarlomo-Rikala M, Kovatich A J, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumours that is more specific than CD34. Mod Pathol 1998; 11: 728–734
  • Isabel Z Y, Fitzpatrick J E. Expression of c-kit (CD117) in spitz naevus and malignant melanoma. J Cutan Pathol 2006; 33: 33–37
  • Montone K T, Van Belle P, Elenitsas R, Elder D E. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol 1997; 10: 939–944
  • Miettinen M, Sobin L H, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117. Mod Pathol 2000; 13: 1134–1142
  • Taniere P, Poncet G, Atieh R, Saurin J C, Henry L, Scoazec J Y. All digestive tumours expressing c-kit are not stromal tumours. Gastroenterol Clin Biol 2002; 26: 1057–1058
  • Martland G T, Goodman A J, Shepherd N A. CD117 expression in oesophageal carcinosarcoma: a potential diagnostic pitfall. Histopathology 2004; 44: 77–80
  • Miettinen M, Lasota J. KIT(CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 2005; 13: 205–220
  • Dow N, Giblen G, Sobin L H, Miettinen M. Gastrointestinal stromal tumours:differential diagnosis. Semin Diagn Pathol 2006; 23: 111–119
  • Dirnhofer S, Zimpfer A, Went P. The diagnostic and predictive role of kit (CD117). Ther Umsch 2006; 63: 273–278
  • Caldwell C B, Bains M S, Burt M. Unusual malignant neoplasms of the esophagus. Oat cell carcinoma, melanoma and sarcoma. J Thorac Cardiovasc Surg 1991; 101: 100–107
  • Ugurel S, Hildenbrand R, Zimpfer A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005; 92: 1398–1405
  • Fiorentini G, Rossi S, Lanzanova G, et al. Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunohistochemical C-KIT (CD117): preliminary results of a compassionate use clinical trial. J Exp Clin Cancer Res 2003; 22(4 Suppl)17–20

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.